Citicoline Concentration in Human Vitreous

• Status: Completed
• Trial end date: 2019-01-31
• Target enrollment: 0
• Participant gender: All

Summary

Elegible patients were included in the study and underwent treatment with a solution of citicoline 1% eye-drops, 0.2% high molecular weight hyaluronic acid and 0.01% benzalkonium chloride prior to surgery. The vitreous samples were taken at the beginning of the surgery and analyzed for qualitative/quantitative determination of vitreous concentration of citicoline and its metabolites by means of high performance liquid chromatography.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Istituto di Ricerca Neuroftalmologia S.r.l.
• Collaborator: Fondazione G.B. Bietti, IRCCS
• Treatments: Benzalkonium Compounds; Cytidine Diphosphate Choline; Hyaluronic Acid; Ophthalmic Solutions

Criteria

Inclusion Criteria:

• age > 18 years

• ability to understand and sign the written informed consent

• diagnosis of epiretinal membrane (ERM) with surgical indication for pars-plana vitrectomy

Exclusion Criteria:

• laser treatments and ocular surgery in the past 6 months

• hypersensitivity to the active ingredients used in the study

• other systemic or ocular diseases different from ERM that could affect the outcome of the study

• aphakia or previous complicated cataract surgery

• intraocular lens (IOL) in the anterior chamber

• treatment with systemic citicoline or other potential neuroprotective agents in the past 6 months

• pregnancy or breastfeeding